HALO Strangle Strategy

HALO (Halozyme Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F.

HALO (Halozyme Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $8.31B, a trailing P/E of 23.72, a beta of 0.88 versus the broader market, a 52-week range of 47.74-82.22, average daily share volume of 1.7M, a public-listing history dating back to 2004, approximately 350 full-time employees. These structural characteristics shape how HALO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.88 places HALO roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a strangle on HALO?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current HALO snapshot

As of May 15, 2026, spot at $67.39, ATM IV 36.10%, IV rank 5.08%, expected move 10.35%. The strangle on HALO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this strangle structure on HALO specifically: HALO IV at 36.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a HALO strangle, with a market-implied 1-standard-deviation move of approximately 10.35% (roughly $6.97 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated HALO expiries trade a higher absolute premium for lower per-day decay. Position sizing on HALO should anchor to the underlying notional of $67.39 per share and to the trader's directional view on HALO stock.

HALO strangle setup

The HALO strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With HALO near $67.39, the first option leg uses a $70.76 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed HALO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 HALO shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$70.76	N/A
Buy 1	Put	$64.02	N/A

HALO strangle risk and reward

Net Premium / Debit: N/A
Max Profit (per contract): Unbounded
Max Loss (per contract): Unbounded
Breakeven(s): None on modeled curve
Risk / Reward Ratio: N/A

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

HALO strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on HALO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use strangle on HALO

Strangles on HALO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the HALO chain.

HALO thesis for this strangle

The market-implied 1-standard-deviation range for HALO extends from approximately $60.42 on the downside to $74.36 on the upside. A HALO long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current HALO IV rank near 5.08% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on HALO at 36.10%. As a Healthcare name, HALO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to HALO-specific events.

HALO strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. HALO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move HALO alongside the broader basket even when HALO-specific fundamentals are unchanged. Always rebuild the position from current HALO chain quotes before placing a trade.

Frequently asked questions

What is a strangle on HALO?: A strangle on HALO is the strangle strategy applied to HALO (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With HALO stock trading near $67.39, the strikes shown on this page are snapped to the nearest listed HALO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are HALO strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the HALO strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 36.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a HALO strangle?: The breakeven for the HALO strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current HALO market-implied 1-standard-deviation expected move is approximately 10.35%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on HALO?: Strangles on HALO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the HALO chain.
How does current HALO implied volatility affect this strangle?: HALO ATM IV is at 36.10% with IV rank near 5.08%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.